Knockdown of IGF2BP1 or IGF2BP3 disrupts YBX1 binding to m6A-tagged mRNAs, including MYC and BCL2, leading to transcript destabilization and impaired AML cell survival [45]. The gene discussed is IGF2BP3; the disease is acute myeloid leukemia.